---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022837"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:55:04.271997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports Q3 net income $1.6M; cash $393.9M; darovasertib registrational trial planned Q1 2023

## Summary
- Cash equivalents and marketable securities of $393.9M as of Sep 30, 2022, sufficient into 2026.
- Q3 net income of $1.6M vs. Q2 net loss of $22.1M; collaboration revenue $29.7M (up from $5.9M).
- Targeting initiation of potential registrational trial for darovasertib + crizotinib in MUM in Q1 2023.
- Initiated IDE397 Phase 2 monotherapy expansion and combination dose escalation with pemetrexed/taxanes.
- Targeting IND for PARG inhibitor IDE161 in Q4 2022 and Pol Theta Helicase FIH study in H1 2023.

## SEC filing metadata
- accession: 0000950170-22-022837
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/0000950170-22-022837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/idya-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022837
- JSON: https://secwatch.observer/filing/0000950170-22-022837.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022837.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/0000950170-22-022837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.